DDM: Decreasing Delirium Through Music in Critically Ill Older Adults

Sponsor
Indiana University (Other)
Overall Status
Recruiting
CT.gov ID
NCT04182334
Collaborator
(none)
160
5
2
57.9
32
0.6

Study Details

Study Description

Brief Summary

Critically ill older adults admitted to the intensive care unit (ICU) are at a higher risk to develop delirium, which predisposes them to longer lengths of ICU and hospital stay, increased in-patient mortality, and higher risk of new acquired cognitive impairment and dementia. Music listening is a non-pharmacological intervention that holds potential to decrease ICU delirium. The investigators propose a randomized controlled trial to evaluate the efficacy of a seven-day slow-tempo music intervention on the primary outcome of delirium/coma free days among mechanically ventilated, critically ill older adults.

Condition or Disease Intervention/Treatment Phase
  • Other: Slow Tempo Music
  • Other: Attention Control
N/A

Detailed Description

One million adults in the United States receive mechanical ventilation for acute respiratory failure in the intensive care units (ICUs) annually and up to 80% of them develop delirium during their ICU stay. Presence of delirium predisposes older adults to immediate in-hospital complications including a longer length of ICU and hospital stay, increased risk of in-patient mortality and elevated costs of care. In addition, ICU delirium is associated with long-term post-discharge complications such as development of cognitive impairment and dementia.

Recent research studies exploring pharmacological strategies to manage ICU delirium have not demonstrated efficacy; a limitation also acknowledged in the Society of Critical Care Medicine 2018 Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption guidelines. Music listening is a non-pharmacological intervention that has shown to decrease over-sedation, anxiety and stress in critically ill patients, factors that could predispose to ICU delirium. Our team is now proposing to conduct a large randomized clinical trial called "Decreasing Delirium through Music (DDM) in Critically Ill Older Adults to evaluate the efficacy of a seven-day slow-tempo music intervention on the primary outcome of delirium/coma free days among mechanically-ventilated older adults admitted to the ICU.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
160 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Slow Tempo Music vs Attention ControlSlow Tempo Music vs Attention Control
Masking:
Triple (Care Provider, Investigator, Outcomes Assessor)
Masking Description:
Only the unblinded study coordinator is aware of randomization. Outcomes assessors are blinded
Primary Purpose:
Treatment
Official Title:
Decreasing Delirium Through Music in Critically Ill Older Adults
Actual Study Start Date :
Mar 5, 2020
Anticipated Primary Completion Date :
Jan 1, 2024
Anticipated Study Completion Date :
Jan 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: Slow Tempo Music

Slow-tempo 60-80 beats per minute relaxing music. The intervention includes two one-hour music listening sessions, once in the morning and once in the evening for up to seven days, delivered through noise-canceling headphones and iPad.

Other: Slow Tempo Music
For up to seven days, enrolled subjects will receive one-hour slow tempo music listening sessions twice daily through noise-cancelling headphones.

Sham Comparator: Attention Control

One-hour sessions consisting of a silence track twice daily delivered through noise-cancelling headphones for up to 7 days.

Other: Attention Control
Subjects will receive a noise cancellation headphone-applied condition identical to the music intervention experimental treatment in twice daily one hour-sessions for up to seven days.

Outcome Measures

Primary Outcome Measures

  1. Days free of delirium and coma [Subjects will be followed up to 28 days post randomization]

    Days free of delirium and coma will be the primary outcome for the trial. Days free of delirium and coma are the number of days after randomization patient is alive free of delirium and not in coma during the seven-day study intervention phase.

Secondary Outcome Measures

  1. Delirium Severity [Subjects will be followed up to 28 days post randomization]

    Delirium severity will be assessed twice daily by trained research assistants using the CAM-ICU-7. CAM-ICU-7 is a seven point scale (0-7), derived from the RASS and the CAM-ICU.

Other Outcome Measures

  1. Pain intensity [4 times daily, before and after each intervention for up to 7 days while in the ICU and then twice daily up to 28 days post randomization]

    Pain will be assessed by trained research assistants utilizing the Critical Care Pain Observation Tool (CPOT), a valid and reliable instrument in critically ill patients with and without delirium.

  2. Anxiety [4 times daily, before and after each intervention for up to 7 days while in the ICU and then twice daily up to 28 days post randomization]

    Anxiety intensity defined as a heightened state of apprehension, agitation, and arousal, will be measured four times daily before and after assigned intervention using a 100-mm Visual Analog Scale-Anxiety (VAS-A).

  3. Cognition [3 months post intervention]

    Cognition will be measured by 4 objective tests of memory, attention, information processing speed, and executive cognitive function (Auditory Verbal Learning Test [AVLT], Digit Span, and Symbol Digit Modalities Test [SDMT], and Controlled Oral Word Association test [COWA]) using a telephone-based administration format, the Indiana University Telephone-Based Assessment of Neuropsychological Status (IU- TBANS) at 3-months post hospital discharge.

  4. Depression [3 months post intervention]

    We will use the Patient Health Questionnaire-9 (PHQ-9) to determine the impact of the music intervention on ICU survivor's mood.

  5. Anxiety [3 months post intervention]

    We will use the Generalized Anxiety Disorder Scale (GAD-7) to determine the impact of the music intervention on ICU survivor's anxiety

Eligibility Criteria

Criteria

Ages Eligible for Study:
50 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Age 50 years or older.

  2. English speaking.

  3. Admitted to the intensive care unit (medical or surgical).

  4. Expected mechanical ventilator support for ≥48 hours.

  5. Consentable through a legally authorized representative.

  6. Have access to a telephone.

Exclusion Criteria:
  1. History of dementing illnesses and other neurodegenerative diseases such as Alzheimer's disease or vascular dementia.

  2. Psychiatric illness which is not well controlled.

  3. Alcohol withdrawal symptoms/concern for withdrawal.

  4. Suspected or confirmed drug intoxication/overdose

  5. Traumatic brain injury, ischemic or hemorrhagic cerebrovascular accident, or undergoing neurosurgery.

  6. Uncorrected hearing or vision impairment including legal blindness.

  7. Incarcerated at the time of study enrollment.

  8. Enrolled in another clinical trial which does not permit co-enrollment.

  9. Any medical condition precluding safe use of headphones such as: skin breakdown, burns, facial or skull fractures.

Contacts and Locations

Locations

Site City State Country Postal Code
1 IU Health West Hospital Avon Indiana United States 46123
2 Eskenazi Hospital Indianapolis Indiana United States 46202
3 IU Health University Hospital Indianapolis Indiana United States 46202
4 Methodist Hospital Indianapolis Indiana United States 46202
5 Mayo Clinic Rochester Rochester Minnesota United States 55905

Sponsors and Collaborators

  • Indiana University

Investigators

  • Principal Investigator: Babar Khan, MD, MS, Indiana University
  • Principal Investigator: Linda Chlan, PhD, RN, Mayo Clinic

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Babar Khan, MD, MS, Associate Professor of Medicine, Indiana University
ClinicalTrials.gov Identifier:
NCT04182334
Other Study ID Numbers:
  • 1906664366
First Posted:
Dec 2, 2019
Last Update Posted:
May 26, 2022
Last Verified:
May 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Babar Khan, MD, MS, Associate Professor of Medicine, Indiana University
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 26, 2022